# Immortality Index — Obstacle & Milestone Reference

> **⚠️ This file is a static snapshot and is not actively maintained.**
> The live platform at [immortality-index.pages.dev](https://immortality-index.pages.dev) is updated every six hours by automated LLM literature scanning and reflects current milestone status far more accurately than this document. Use this file to copy obstacle and milestone definitions, explore the dependency graph, or build upon it. Do not rely on checked/unchecked states here — consult the live platform instead.

---

## Overview

The Immortality Index tracks **24 research obstacles** across two engineering tracks. Each obstacle has **4 binary milestones** — concrete, falsifiable achievements that peer-reviewed literature either confirms or does not. The live platform's AI scanning updates milestone completion every six hours.

- **Track 01 · Somatic Genetic Fidelity** — 14 obstacles, 56 milestones
- **Track 02 · Nanoscale Biomedical Systems** — 10 obstacles, 40 milestones

**System-Level Integration Bottlenecks (SLIB):** Denoted with ⚠️. Phase 5 obstacles in each track representing cross-system integration requirements that cannot be validated until upstream milestones in both tracks are simultaneously satisfied.

---

## Track 01 · Somatic Genetic Fidelity

### Phase 1 — Reprogramming Layer

#### G-1.1 · In Vivo Epigenetic Reprogramming Proof-of-Concept

**Theoretical Target:** Demonstrate safe, transient, partial epigenetic reprogramming in a living mammalian system — reverting epigenetic age markers without triggering oncogenic dedifferentiation or loss of somatic cell identity.

**Milestones:**
1. Partial OSK or OSKM reprogramming in post-mitotic mammalian neurons in vivo demonstrated without tumorigenesis (n ≥ 30)
2. Epigenetic clock reversal (Horvath/DunedinPACE) ≥30% confirmed in live murine tissue via pyrosequencing or RRBS with independent replication
3. Reprogramming achieved without loss of cell-type-specific transcriptomic identity (scRNA-seq showing <5% transcriptional identity deviation)
4. Non-human primate (NHP) in vivo partial reprogramming trial with ≥6-month safety follow-up, zero oncogenic events

---

#### G-1.2 · Systemic Senescent Cell Clearance Engine

**Theoretical Target:** Develop a scalable, systemic senolytic/senomorphic intervention capable of eliminating ≥80% of p16^INK4a-positive senescent cells across all major organ systems in a living mammal, with minimal off-target elimination of proliferating progenitor cells.

**Milestones:**
1. CAR-T or bispecific antibody platform selectively eliminates ≥80% p16^INK4a+ cells in murine model confirmed by IHC and single-cell profiling
2. Off-target elimination of non-senescent progenitor cells confirmed <5% using lineage tracing
3. Multi-organ clearance demonstrated across ≥5 distinct tissue types in the same in vivo experiment
4. NHP or large-animal senolytic study demonstrates ≥50% senescent burden reduction system-wide with sustained functional improvement at 12-month follow-up

---

#### G-1.3 · Full-Body Vascular Gene Delivery Network

**Theoretical Target:** Establish a gene delivery infrastructure capable of transfecting >90% of all cell types across all organ systems — including CNS beyond the blood-brain barrier — with a single systemic administration, achieving <0.01% off-target genomic integration events.

**Milestones:**
1. Novel AI-designed AAV capsid validated for pan-organ biodistribution in large animal model (porcine/NHP)
2. Ionizable LNP achieves >70% CNS transfection efficiency post-IV in primate without hepatotoxicity (LFT within 2× ULN)
3. Multiplexed delivery vehicle demonstrates functional co-delivery in ≥3 distinct tissue types simultaneously
4. Phase I/II human trial demonstrates systemic biodistribution with off-target integration <0.01% confirmed by whole-genome sequencing

---

#### G-1.4 · Stem Cell Telomere Maintenance Switch

**Theoretical Target:** Develop a controllable, reversible mechanism to restore and maintain telomere length in tissue-specific stem cell pools to youthful baseline (>10 kb) without constitutive telomerase activation or associated oncogenic risk.

**Milestones:**
1. Inducible TERT expression restores mean telomere length to >10 kb in HSCs and intestinal stem cells in aged murine model without chromosomal instability
2. Temporal control demonstrated: TERT induction activatable and fully suppressible within a 72h window confirmed by RT-qPCR and telomere FISH
3. Zero oncogenic events in 12-month murine cohort (n ≥ 50) following controlled telomere maintenance cycles
4. Ex vivo expansion of NHP stem cells with restored telomere length demonstrates maintained multi-lineage differentiation capacity

---

### Phase 2 — Genomic Fidelity Layer

#### G-2.1 · Heterochromatin Pioneer Factor Decoupling

**Theoretical Target:** Selectively reactivate silenced heterochromatic longevity-associated loci (SIRT1, FOXO3, AMPK pathway regulators) without global heterochromatin destabilisation, retrotransposon de-repression, or activation of co-localised oncogenes.

**Milestones:**
1. CRISPR-dCas9-p300 achieves targeted H3K27ac deposition at ≥3 longevity-associated loci with <0.5% off-target activations confirmed by ChIP-seq
2. Delivery system avoids retrotransposon (LINE-1, SINE) de-repression — confirmed by transposable element expression profiling (<2× fold change)
3. Reactivated loci maintain expression across ≥5 cell divisions without vector persistence, confirming stable epigenetic inheritance
4. Murine in vivo experiment demonstrates concurrent reactivation of ≥2 longevity loci with measurable physiological improvement (p < 0.01, independently replicated)

---

#### G-2.2 · Sub-Letter Nucleotide Absolute Precision Editing

**Theoretical Target:** Achieve single-nucleotide correction of pathogenic point mutations in post-mitotic somatic cells in vivo — on-target efficiency ≥90%, off-target mutation rate ≤1 event per 10^9 base pairs per editing round.

**Milestones:**
1. Base editor or prime editor achieves ≥90% on-target correction in primary human post-mitotic neurons in vitro (n ≥ 3 independent experiments, no immortalised cell lines)
2. Whole-genome sequencing of ≥100 edited clones confirms off-target indel rate ≤1 per 10^9 bp — independently validated by two research groups
3. In vivo murine liver correction (n ≥ 40) with ≥70% efficiency confirmed by deep sequencing
4. NHP in vivo precision editing trial with 6-month safety follow-up — confirmed off-target rate ≤1 per 10^9 bp across ≥3 organ systems

---

### Phase 3 — Synthetic Biology Layer

#### G-3.1 · Synthetic Membraneless Nuclear Enclave Formation

**Theoretical Target:** Engineer self-assembling, phase-separated synthetic compartments within the nucleus that sequester DNA repair factors at ≥10× local concentration, improving double-strand break resolution efficiency by ≥50%.

**Milestones:**
1. Engineered condensate self-assembles in human primary fibroblasts confirmed by super-resolution microscopy (STORM/PALM) showing >10× local concentration of target repair factors
2. γH2AX foci resolution rate improved ≥50% vs. unmodified controls (p < 0.01)
3. Condensates demonstrate cell-cycle-dependent dissolution without chromosomal segregation defects across ≥5 mitotic events per cell line
4. Murine in vivo experiment demonstrates ≥40% improvement in DSB repair efficiency in aged hepatocytes vs. unmodified controls

---

#### G-3.2 · 12-Hour Cryptographic Logic Gate Wiring

**Theoretical Target:** Implement a synthetic genetic Boolean logic circuit in mammalian somatic cells capable of executing a 12-hour programmable epigenetic modification cycle — integrating ≥3 environmental sensor inputs and producing a verifiable, reversible chromatin output.

**Milestones:**
1. Three-input AND gate successfully wired in human primary cells with output fidelity ≥95% across all 8 input combinations
2. 12-hour autonomous cyclic execution demonstrated in vitro across ≥10 consecutive cycles without circuit drift >5%
3. Chromatin output confirmed reversible: target locus methylation state togglable ≥5× without accumulation of off-target methylation events
4. Murine in vivo delivery shows maintained gate fidelity ≥85% at 30-day post-injection with no inflammatory response above baseline

---

#### G-3.3 · Protected Somatic Identity Tag Binding

**Theoretical Target:** Develop and stably integrate a cryptographically structured synthetic identity tag into non-coding somatic cell genome — readable by co-engineered nanoscale sensor complexes — persisting across ≥200 cell divisions without methylation silencing, recombination, or deletion.

**Milestones:**
1. Synthetic identity tag survives ≥200 consecutive cell divisions without sequence mutation, confirmed by nanopore long-read sequencing
2. Tag readable by co-engineered protein sensor with ≥99% specificity confirmed by ChIP-seq and competitive binding assay
3. Tag remains unmethylated and transcriptionally accessible after standard cellular stress (UV, H₂O₂, 43°C heat shock) confirmed by ATAC-seq
4. In vivo murine experiment confirms tag persistence in ≥80% of liver hepatocytes at 12-month post-integration, confirmed by whole-genome sequencing

---

### Phase 4 — Intercellular Communication Layer

#### G-4.1 · Intercellular Tunneling Nanotube Synthesis

**Theoretical Target:** Engineer programmable tunneling nanotubes (TNTs) between somatic cells capable of directional transfer of specific molecular cargo at controlled rates, without triggering innate immune activation.

**Milestones:**
1. Synthetic TNT formation confirmed by electron microscopy showing lumen diameter 50–700 nm and length ≥50 μm
2. Directional cargo transfer of fluorescently tagged mRNA: ≥60% delivery to target cells vs. <5% to non-target cells
3. TNT formation does not trigger TLR-mediated innate immune response (IL-6, TNF-α, IFN-β ≤1.5× ULN vs. unstimulated controls)
4. In vivo murine experiment confirms directed molecular cargo transfer between adjacent hepatocytes with ≥40% efficiency

---

#### G-4.2 · Decentralized Intercellular Transcriptomic Error-Correction Networks

**Theoretical Target:** Establish a cell-autonomous, paracrine-mediated error-correction network in which somatic cells with detected transcriptomic deviation broadcast standardised correction signals to neighbours — reducing population-level transcriptomic drift by ≥60%.

*Formerly referred to as "P2P Re-Flashing." Formal designation: Paracrine-Mediated Epigenetic and Transcriptomic Remodeling.*

**Milestones:**
1. Synthetic paracrine signalling construct detects transcriptomic deviation (≥1.5× fold change in ≥50 housekeeping genes) and triggers measurable secretion of engineered correction vesicles confirmed by nanoparticle tracking analysis
2. Neighbour cells receiving correction vesicles demonstrate ≥40% reduction in transcriptomic deviation score confirmed by bulk RNA-seq (n ≥ 3 biological replicates)
3. Correction signal propagation demonstrated across ≥3 cell layers without efficacy falling below 30%, confirmed by spatial transcriptomics
4. Murine in vivo experiment: ≥30% reduction in clonal transcriptomic heterogeneity after 28-day activation vs. unmodified littermates

---

#### G-4.3 · Homing Matrix Stem Cell Routing

**Theoretical Target:** Engineer a synthetic extracellular guidance cue system that routes tissue-specific stem cells to sites of accumulated somatic damage with ≥5× enrichment versus undamaged tissue.

**Milestones:**
1. Synthetic homing construct achieves ≥5× stem cell enrichment at damage sites vs. undamaged tissue in 3D organoid model
2. Recruited stem cells demonstrate ≥80% correct lineage commitment without ectopic marker expression
3. Fibrosis markers (collagen-I, α-SMA, TGF-β) remain ≤1.5× baseline at recruitment sites at 14-day post-homing timepoint
4. In vivo murine tissue damage model demonstrates ≥4× functional stem cell enrichment with improved healing metrics vs. controls (p < 0.05)

---

### Phase 5 — System-Level Integration Bottleneck (SLIB)

#### G-5.1 · ⚠️ SLIB: Full Chromosomal Integration and Identity Verification

**Theoretical Target:** Demonstrate simultaneous, coordinated operation of all Track 01 subsystems within a single mammalian organism, with confirmed systemic somatic identity integrity across ≥10^12 cells.

**Milestones:**
1. All Track 01 subsystems co-delivered and co-expressed in a single aged murine model without mutual interference confirmed by multi-omics profiling
2. Systemic somatic identity verification: identity tag readable in ≥85% of sampled cells across ≥5 tissue types at 6-month timepoint
3. Measurable multi-system functional rejuvenation — biological age reduction ≥20% by two independent epigenetic clocks in same organism
4. Safety at 12-month follow-up: zero oncogenic events, ANA panel negative, karyotype stable by whole-genome sequencing

---

#### G-5.2 · Somatic Identity Triage and External Intervention Loop

**Theoretical Target:** Implement a 2-of-3 spatial quorum logic gate. If a permanent somatic cell experiences dual identity-string corruption and cryptographic checksum mismatch, the cell must: (i) cease functional operations and downregulate metabolic activity below 20% baseline; (ii) induce micro-scale Somatic Identity Triage and Localized Fibrotic Encapsulation to prevent lineage-infidelity propagation; and (iii) continuously secrete a bio-orthogonal tracking peptide into the vascular system at ≥10 fmol/mL, triggering targeted retrieval by Track 02 nanorobotic units or systemic clinical assays. Prevents Byzantine fault cascade propagation across the somatic network.

**Milestones:**
1. In vitro human 3D organoid validation: dual-corruption trigger activates metabolic shutdown (<20% baseline ATP by luminescence assay), fibrotic encapsulation (Sirius Red staining), and bio-orthogonal peptide secretion (≥10 fmol/mL by LC-MS/MS) in ≥90% of triggered cells with <2% false-positive rate in uncorrupted neighbours
2. Murine in vivo model: engineered cells with dual-corruption trigger confirm triage activation within 24h, fibrotic capsule at ≥85% of sites, vascular peptide ≥10 fmol/mL by systemic assay; host biological age unchanged at 90-day follow-up (no SASP-mediated bystander aging)
3. Large animal / NHP validation across ≥3 tissue compartments: independent triage activation in each, no cross-compartment corruption propagation, vascular peptide ≥10 fmol/mL by clinical-grade ELISA, host biological age within ±5% of baseline at 180-day follow-up
4. Human Phase I safety and biomarker detection trial (n ≥ 12): vascular peptide ≥10 fmol/mL in serum by LC-MS/MS within 72h; no grade ≥2 adverse events (CTCAE v5.0); CRP ≤1.5× ULN at 30 days; no fibrotic lesion expansion beyond 5mm by MRI

---

## Track 02 · Nanoscale Biomedical Systems

### Phase 1 — Propulsion & Processing Layer

#### N-1.1 · Remote Mechanical Micro-Propulsion

**Milestones:**
1. Helical or flagellar nanorobot propulsion demonstrated in synthetic blood plasma at ≥10 μm/s with directional accuracy ≥85%
2. Biocompatibility: haemolysis ≤0.1%, platelet activation <5% above baseline (CD62P), complement SC5b-9 ≤1.5× ULN in human whole-blood assay
3. Magnetic or acoustic field-guided navigation through 500 μm vascular phantom with ≥3 branching junctions, ≥80% successful routing
4. In vivo murine intravascular deployment — target organ specificity ≥60% vs. non-target organs, no acute toxicity at 72h

---

#### N-1.2 · Sub-10-Attojoule Reversible Neuromorphic Processing

**Milestones:**
1. Molecular logic gate executes AND/OR/NOT operations at ≤10 aJ per operation confirmed by calorimetric assay
2. Non-destructive state readout: same element read ≥100× without state corruption
3. Full operational stability at 37°C in physiological buffer (pH 7.4, 150 mM NaCl) for ≥72h without >5% performance degradation
4. ≥3 logic elements integrated into functional circuit executing 2-bit pattern recognition in cell culture medium at ≥95% accuracy

---

#### N-1.3 · Low-Frequency Acoustic Wave-Guiding Mesh

**Milestones:**
1. Acoustic waveguide mesh transmits ≥4-bit data packet at ≤1 MHz with SNR ≥20 dB in tissue-mimicking phantom
2. Simultaneous coordination of ≥100 nanoscale elements in 1 cm³ tissue phantom — positional uncertainty ≤50 μm
3. Tissue heating <0.5°C rise during 30-minute continuous operation in ex vivo porcine tissue confirmed by fibre-optic thermometry
4. In vivo murine study: mesh elements maintain ≥80% communication fidelity at 30-day post-implantation confirmed by external acoustic interrogation

---

### Phase 2 — Assembly Layer

#### N-2.1 · Scaffolded DNA Origami Assembly Molds

**Milestones:**
1. DNA origami scaffold with ≥200 addressable positions folds with ≥85% yield confirmed by cryo-EM with ≤5 nm positional precision
2. Functional protein cargo integrated at ≥70% of target positions with confirmed activity
3. Scaffold stable for ≥48h in physiological buffer (PBS, 37°C) with <10% structural degradation confirmed by AFM
4. In cellulo: scaffold introduced into human primary cells without TLR9-mediated immune response (IL-6, IFN-α ELISA ≤1.5× ULN)

---

#### N-2.2 · True Digital-to-Physical Molecular Assembly

**Milestones:**
1. Automated assembler produces ≥10-mer synthetic polymer from digital sequence input with ≥99% per-monomer fidelity confirmed by mass spectrometry
2. System scales to ≥20-mer assembly maintaining ≥99% overall sequence fidelity confirmed by tandem MS/MS
3. Assembly cycle fully autonomous with cycle time ≤4h per 20-mer
4. Assembled structures demonstrate designed functional activity within ±10% of computationally predicted value

---

#### N-2.3 · Microscopic Radiation-Hardened Structural Hulls

**Milestones:**
1. Hull demonstrates ≥90% protection of encapsulated enzyme activity after 10 Gy γ-irradiation vs. unshielded control
2. Hull optically transparent (>85% transmission, 400–900 nm), mechanically stable (Young's modulus ≥1 GPa), ≤50 ag mass per unit
3. Biocompatibility confirmed: no macrophage activation or complement cascade in human whole-blood assay
4. In vivo murine: hull-encapsulated unit retains ≥70% activity after whole-body 5 Gy irradiation at 72h

---

### Phase 3 — Tissue Interface Layer

#### N-3.1 · Selective Enzyme Somatic Identity Triage and Localized Fibrotic Encapsulation

*Targeted degradation of pathological fibrotic matrices. Formerly referred to as "Scar Tissue" clearance.*

**Milestones:**
1. Enzyme cocktail achieves ≥80% degradation of pathological collagen-I matrix in 3D fibrotic hydrogel with ≥90% viability of surrounding healthy fibroblasts
2. Targeting specificity: ≥85% of degradation activity contained within 200 μm radius of deployment
3. Secondary fibrosis absent at 7-day post-treatment: TGF-β, CTGF ≤1.2× baseline, no α-SMA upregulation in surrounding tissue
4. In vivo murine fibrosis model: ≥50% reduction in fibrotic burden at treatment sites, no expansion to adjacent tissue at 21-day follow-up

---

#### N-3.2 · Molecular Extracellular Matrix Floor Laying

**Milestones:**
1. Single nanoassembly unit deposits functional ECM-like matrix at ≥1 μm²/h confirmed by time-lapse AFM
2. Matrix composition matched to target tissue proteomic signature within ≤15% deviation across ≥20 quantified proteins by LC-MS/MS
3. Deposited matrix supports attachment and functional differentiation of primary human cells (≥80% correct lineage commitment vs. native ECM)
4. In vivo murine implant: nanoassembly-deposited matrix integrates with host tissue without fibrous encapsulation at 30-day histology

---

#### N-3.3 · Decentralized Near-Field Direct Code Flashing

*Formerly referred to as "Near-Field Direct Code Flashing." Part of the Decentralized Intercellular Transcriptomic Error-Correction Networks.*

**Milestones:**
1. Near-field transceiver transmits ≥256-bit payload to receiving nanounit within 10 μm at ≥99.9% fidelity across ≥10,000 transmission cycles
2. Transmission does not alter membrane potential or action potential firing pattern in adjacent neurons (Vm deviation ≤2 mV by patch-clamp)
3. Code update reprograms nanounit operational parameters mid-deployment — updated function confirmed within 60s of instruction receipt
4. In vivo murine: near-field code flash confirmed in implanted nanounits at 30-day post-implantation, updated function confirmed by reporter output

---

### Phase 4 — System-Level Integration Bottleneck (SLIB)

#### N-4.1 · ⚠️ SLIB: Mass Swarm Cohesion and Systemic Integration

**Theoretical Target:** Demonstrate fully coordinated operation of all Track 02 nanoscale subsystems as a unified swarm within a living mammalian organism, with confirmed systemic task completion and bio-clearance.

**Milestones:**
1. All Track 02 subsystems co-deployed via IV in single murine organism — swarm executes assigned tissue navigation and cargo delivery with ≥70% success rate
2. Acoustic mesh maintains real-time swarm coordination throughout 60-minute operation window in live animal confirmed by external ultrasound
3. Bio-clearance: ≥95% of swarm units cleared from circulation within 72h, no off-target organ accumulation above 1% injected dose
4. NHP swarm deployment: full subsystem integration with ≥60% task completion efficiency and confirmed bio-clearance within 7 days (CTCAE Grade 0–1)

---

## Appendix — Nomenclature Reference

| Informal / Legacy Term | Formal RLI Designation |
|---|---|
| Immortality Index | The Radical Longevity Index (RLI) / Framework for Engineered Negligible Senescence |
| Boss Hurdle | System-Level Integration Bottleneck (SLIB) |
| P2P Re-Flashing | Decentralized Intercellular Transcriptomic Error-Correction Networks |
| Re-flashing neighbors | Paracrine-Mediated Epigenetic and Transcriptomic Remodeling |
| Quarantine Mode / Scar Tissue | Somatic Identity Triage and Localized Fibrotic Encapsulation |

---

*Immortality Index · CC BY 4.0 · [immortality-index.pages.dev](https://immortality-index.pages.dev)*
